Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin effect on beta cell function in drug-naive T2D
NCT00260156Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing vildagliptin with Placebo (2 arms). Primary endpoint: Change from baseline in hyperglycemia and arginine-stimulated first phase insulin secretion at 52 weeks. Started Nov 2005; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00260156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00260156.